Genetic Polymorphisms of Matrix Metalloproteinases and Their Inhibitors in Potentially Malignant and Malignant Lesions of the Head and Neck

Overview

Journal J Biomed Sci

Publisher Biomed Central

Specialty Biology

Date 2010 Feb 16

PMID 20152059

Citations 31

Authors

Ajay Kumar Chaudhary

Mamta Singh

Alok C Bharti

Kamlesh Asotra

Shanthy Sundaram

Ravi Mehrotra

Affiliations

Soon will be listed here.

Abstract

Matrix metalloproteinases (MMPs) are a family of zinc-dependent proteinases that are capable of cleaving all extra cellular matrix (ECM) substrates. Degradation of matrix is a key event in progression, invasion and metastasis of potentially malignant and malignant lesions of the head and neck. It might have an important polymorphic association at the promoter regions of several MMPs such as MMP-1 (-1607 1G/2G), MMP-2 (-1306 C/T), MMP-3 (-1171 5A/6A), MMP-9 (-1562 C/T) and TIMP-2 (-418 G/C or C/C). Tissue inhibitors of metalloproteinases (TIMPs) are naturally occurring inhibitors of MMPs, which inhibit the activity of MMPs and control the breakdown of ECM. Currently, many MMP inhibitors (MMPIs) are under development for treating different malignancies. Useful markers associated with molecular aggressiveness might have a role in prognostication of malignancies and to better recognize patient groups that need more antagonistic treatment options. Furthermore, the introduction of novel prognostic markers may also promote exclusively new treatment possibilities, and there is an obvious need to identify markers that could be used as selection criteria for novel therapies. The objective of this review is to discuss the molecular functions and polymorphic association of MMPs and TIMPs and the possible therapeutic aspects of these proteinases in potentially malignant and malignant head and neck lesions. So far, no promising drug target therapy has been developed for MMPs in the lesions of this region. In conclusion, further research is required for the development of their potential diagnostic and therapeutic possibilities.

Citing Articles

Understanding the role of nerves in head and neck cancers - a review.

Rutkowski K, Gola M, Godlewski J, Starzynska A, Marvaso G, Mastroleo F Oncol Rev. 2025; 18:1514004.

PMID: 39906323 PMC: 11791411. DOI: 10.3389/or.2024.1514004.

Hypoxic Effects on Matrix Metalloproteinases' Expression in the Tumor Microenvironment and Therapeutic Perspectives.

Gonzalez-Avila G, Sommer B, Flores-Soto E, Aquino-Galvez A Int J Mol Sci. 2023; 24(23).

PMID: 38069210 PMC: 10707261. DOI: 10.3390/ijms242316887.

Genetic Variants in Matrix Metalloproteinases (rs3025058) and (rs3918242) Associated with Colonic Diverticulosis.

Nehring P, Gromadzka G, Jastrzebski M, Przybylkowski A Medicina (Kaunas). 2023; 59(11).

PMID: 38004080 PMC: 10673370. DOI: 10.3390/medicina59112031.

BMSC-HNC Interaction: Exploring Effects on Bone Integrity and Head and Neck Cancer Progression.

Eichberger J, Froschhammer D, Schulz D, Scholz K, Federlin M, Ebensberger H Int J Mol Sci. 2023; 24(19).

PMID: 37833873 PMC: 10573008. DOI: 10.3390/ijms241914417.

Opposing MMP-9 Expression in Mesenchymal Stromal Cells and Head and Neck Tumor Cells after Direct 2D and 3D Co-Culture.

Waltera A, Schulz D, Schaefer N, Stoeckl S, Pion E, Haerteis S Int J Mol Sci. 2023; 24(2).

PMID: 36674806 PMC: 9861345. DOI: 10.3390/ijms24021293.

References

Fassina G, Ferrari N, Brigati C, Benelli R, Santi L, Noonan D . Tissue inhibitors of metalloproteases: regulation and biological activities. Clin Exp Metastasis. 2001; 18(2):111-20. DOI: 10.1023/a:1006797522521. View

Ra H, Parks W . Control of matrix metalloproteinase catalytic activity. Matrix Biol. 2007; 26(8):587-96. PMC: 2246078. DOI: 10.1016/j.matbio.2007.07.001. View

Stetler-Stevenson W, Yu A . Proteases in invasion: matrix metalloproteinases. Semin Cancer Biol. 2001; 11(2):143-52. DOI: 10.1006/scbi.2000.0365. View

Nelson A, Fingleton B, Rothenberg M, Matrisian L . Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol. 2000; 18(5):1135-49. DOI: 10.1200/JCO.2000.18.5.1135. View

Stetler-Stevenson W, Liotta L, Kleiner Jr D . Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J. 1993; 7(15):1434-41. DOI: 10.1096/fasebj.7.15.8262328. View

DeClerck Y, Mercurio A, Stack M, Chapman H, Zutter M, Muschel R . Proteases, extracellular matrix, and cancer: a workshop of the path B study section. Am J Pathol. 2004; 164(4):1131-9. PMC: 1615345. DOI: 10.1016/S0002-9440(10)63200-2. View

Overall C, Lopez-Otin C . Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer. 2002; 2(9):657-72. DOI: 10.1038/nrc884. View

Nishioka Y, Sagae S, Nishikawa A, Ishioka S, Kudo R . A relationship between Matrix metalloproteinase-1 (MMP-1) promoter polymorphism and cervical cancer progression. Cancer Lett. 2003; 200(1):49-55. DOI: 10.1016/s0304-3835(03)00411-7. View

Strati K, Pitot H, Lambert P . Identification of biomarkers that distinguish human papillomavirus (HPV)-positive versus HPV-negative head and neck cancers in a mouse model. Proc Natl Acad Sci U S A. 2006; 103(38):14152-7. PMC: 1599927. DOI: 10.1073/pnas.0606698103. View

10.

Vairaktaris E, Vassiliou S, Nkenke E, Serefoglou Z, Derka S, Tsigris C . A metalloproteinase-9 polymorphism which affects its expression is associated with increased risk for oral squamous cell carcinoma. Eur J Surg Oncol. 2007; 34(4):450-5. DOI: 10.1016/j.ejso.2007.03.024. View

11.

Tasci A, Tugcu V, Ozbek E, Ozbay B, Simsek A, Koksal V . A single-nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances bladder cancer susceptibility. BJU Int. 2007; 101(4):503-7. DOI: 10.1111/j.1464-410X.2007.07315.x. View

12.

Sanderson R, Ironside J . Squamous cell carcinomas of the head and neck. BMJ. 2002; 325(7368):822-7. PMC: 1124330. DOI: 10.1136/bmj.325.7368.822. View

13.

Mehrotra R, Pandya S, Chaudhary A, Kumar M, Singh M . Prevalence of oral pre-malignant and malignant lesions at a tertiary level hospital in Allahabad, India. Asian Pac J Cancer Prev. 2008; 9(2):263-5. View

14.

Singh H, Jain M, Mittal B . MMP-7 (-181A>G) promoter polymorphisms and risk for cervical cancer. Gynecol Oncol. 2008; 110(1):71-5. DOI: 10.1016/j.ygyno.2008.03.007. View

15.

Sparano J, Bernardo P, Stephenson P, Gradishar W, Ingle J, Zucker S . Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J Clin Oncol. 2004; 22(23):4683-90. DOI: 10.1200/JCO.2004.08.054. View

16.

Sternlicht M, Werb Z . How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001; 17:463-516. PMC: 2792593. DOI: 10.1146/annurev.cellbio.17.1.463. View

17.

DeClerck Y, Perez N, Shimada H, Boone T, Langley K, Taylor S . Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res. 1992; 52(3):701-8. View

18.

McColgan P, Sharma P . Polymorphisms of matrix metalloproteinases 1, 2, 3 and 9 and susceptibility to lung, breast and colorectal cancer in over 30,000 subjects. Int J Cancer. 2009; 125(6):1473-8. DOI: 10.1002/ijc.24441. View

19.

Birkedal-Hansen H, Moore W, Bodden M, Windsor L, DeCarlo A, Engler J . Matrix metalloproteinases: a review. Crit Rev Oral Biol Med. 1993; 4(2):197-250. DOI: 10.1177/10454411930040020401. View

20.

Freije J, Balbin M, Pendas A, Sanchez L, Puente X, Lopez-Otin C . Matrix metalloproteinases and tumor progression. Adv Exp Med Biol. 2003; 532:91-107. DOI: 10.1007/978-1-4615-0081-0_9. View